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Patients receiving thoracic radiation often develop pulmonary injury
and fibrosis. Currently, there are no effective measures to prevent or
treat these conditions. We tested whether blockade of the chemo-
kine, CC chemokine ligand (CCL) 3, and its receptors, CC chemokine
receptor (CCR) 1 and CCR5, can prevent radiation-induced lung
inflammation and fibrosis. C57BL/6J mice received thoracic radia-
tion, and the interaction of CCL3 with CCR1 or CCR5 was blocked
using genetic techniques, or by pharmacologic intervention. Lung
inflammation was assessed by histochemical staining of lung tissue
and by flow cytometry. Fibrosis was measured by hydroxyproline
assays and collagen staining, and lung function was studied by
invasive procedures. Irradiated mice lacking CCL3 or its receptor,
CCR1, did not develop the lung inflammation, fibrosis, and decline in
lung function seen in irradiated wild-type mice. Pharmacologic
treatment of wild-type mice with a small molecule inhibitor of
CCR1 also prevented lung inflammation and fibrosis. By contrast,
mice lacking CCR5 were not protected from radiation-induced injury
and fibrosis. The selective interaction of CCL3 with its receptor,
CCR1, is critical for radiation-induced lung inflammation and fibro-
sis, and these conditions can be largely prevented by a small
molecule inhibitor of CCR1.
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Thoracic radiation is commonly used to treat cancers of the lung,
esophagus, thymus, breast, and lymph nodes. Whereas radiation
treatments can reduce or eliminate tumor burden, many patients
also develop lung inflammation and fibrosis, which is associated
with considerable morbidity and mortality. The histopathologic
changes to the irradiated lung are well described, and include
oxidative damage to fibroblasts and the vascular endothelium,
followed by vascular congestion, inflammation, mesenchymal cell
proliferation, extracellular matrix deposition, and extensive pa-
renchymal remodeling (1). As with other forms of fibrosis, the
cellular and molecular events that give rise to these conditions are
poorly understood, and there are currently no effective treatments
for them. Although corticosteroids are frequently administered to
these patients, this approach often fails to improve the prognosis
for many patients, and is associated with numerous side effects.
Radiation-induced lung injury can be divided into two phases:
an early inflammatory phase, and a late fibroproliferative phase.
The inflammatory phase generally occurs within 1–3 months after
irradiation, and is characterized by alveolar cell depletion and
inflammatory cell accumulation. The fibroproliferative phase oc-
curs approximately 6 months after irradiation, and includes fibro-
blast proliferation, collagen accumulation, and alveolar septal
thickening (2). Although the pulmonary inflammation seen dur-
ing the early phase is thought to trigger the later fibroprolifer-
ative phase, the specific leukocyte subsets and molecules that
link these two phases have not been identified (3, 4).
Chemokines are low–molecular weight, secreted proteins that
promote directional chemotaxis of leukocyte migration through
7-TM–spanning, G protein–coupled receptors (5). Chemokines
are divided into four subgroups based on the organization of the
first pair of conserved cysteine motifs (6). Blocking leukocyte
recruitment to inflamed tissue should, therefore, be beneficial in
some inflammatory diseases (6–8). Certainly, chemokines are im-
portant mediators in the pathogenesis of lung injury in several
settings (9–11). For example, binding of the chemokine, CXC, to
its receptor, CXCR2, drives neutrophil recruitment in hypoxia-
induced lung injuries (11). We and others have also found that
a different chemokine, CC chemokine ligand (CCL) 3, is required
for leukocyte recruitment in several models of lung inflammation,
including infections with influenza virus (12) or Aspergillus
fumigatus (13), and in graft-versus-host disease (14). Here, we
show that both CCL3 and its receptor, CC chemokine receptor
(CCR) 1, are required for radiation-induced lung inflammation
and fibrosis, and that these conditions can be largely prevented
with a small molecule inhibitor of CCR1.
MATERIALS AND METHODS
Animals
All animal studies were approved by the institutional animal care and
use committee at University of North Carolina at Chapel Hill (Chapel
Hill, NC). All mice were on a fully backcrossed C57Bl/6 background
with age-matched controls. Ccl32/2 mice were described previously
(12). Ccr12/2 mice were purchased from Jackson Laboratories (Bar
Harbor, ME), and Ccr52/2 mice were obtained from Dr. William
Kuziel (Protein Design Laboratories, Incline Village, NV).
Thoracic Irradiation
Anesthetized mice at the age of 10–12 weeks were immobilized, with
a lead shield excluding all but the thoracic cavity. Animals were then
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irradiated with a single dose of 14.5 Gy from a cesium source (J. L.
Shepherd and Associates, San Fernando, CA) at a dose rate of 1.65 Gy/min.
LD50 for C57BL/6J mice is 14.5 Gy. At this dose, survival is sufficient to
permit adequate numbers of animals for long-term analyses.
Histopathology and Morphometric Analyses
Lung sections were stained with hematoxylin and eosin for routine
histology, and with Masson’s trichrome for collagen analysis. A total of
10 representative 53 images were analyzed in a blinded fashion for
septal thickening using ImageJ software (National Institutes of Health,
Bethesda, MD) software, as previously described (15).
Quantification of Lung Hydroxyproline
The right lung was acid digested and hydroxyproline content was an-
alyzed as previously (16) (see the online supplement for details).
Measurements of Lung Mechanics
Anesthetized mice were mechanically ventilated on a computer-
controlled small-animal ventilator (Scireq, Montreal, PQ, Canada) at
350 breaths/min, 6 ml/kg tidal volume, and positive end-expiratory
pressure of 3–4 cm H2O. Lung mechanics measurements were per-
formed as previously described (17).
Flow Cytometric Analyses
Excised lungs were minced and digested in collagenase A for 1 hour.
Red blood cells were lysed with ACK buffer, and resultant nucleated
cells separated on a 20% Percoll gradient were stained with PE- or
FITC-labeled monoclonal antibodies to Gr1, FoxP3, CD3, CD4, CD8,
and F4/80 (Pharmingen, San Jose, CA), and analyzed on a FACScan
with Cytomation software (Becton-Dickinson, Franklin Lakes, NJ).
Gene Expression Analyses
Lung RNA was extracted and quantitative real-time PCR was per-
formed using TaqMan gene expression assays (Applied Biosystems,
Foster City, CA). Data were analyzed as previously described (18).
Analyses of Cytokines
Mouse lungs were homogenized in 1 ml of protease inhibitors and
centrifuged at 1,4000 rpm for 15 minutes at 48C. Collected lung su-
pernatants were subjected to quantitative ELISA measurements using
Quantikine CCL3 and Promega Transforming Growth Factor (TGF)–b1
Emax Immunoassay systems (Madison, WI).
Treatment with the CCR1 Antagonist, BX-471
Based on doses used in previous studies (19–22), the irradiated mice
received twice-daily subcutaneous injections of 30 mg/kg BX-471 in
40% cyclodextrin (Sigma, St. Louis, MO) or vehicle only. Mice were
killed 32 weeks for analyses after irradiation.
Lewis Lung Carcinoma Model and Irradiation
Lewis lung carcinoma cells (5 3 104) in 0.05 ml of PBS were injected
subcutaneously into the anterior chest wall of wild-type (WT) and
CCR1-deficient mouse. Tumor growth was assessed by using calipers
for two dimensional tumor measurements (see the online supplement
for details).
Statistical Analysis
Two-tailed Student’s t test was performed to compare the results of
hydroxyproline content, quantitative histological analyses, lung func-
tion measurement, and flow cytometric analyses. Survival analyses
were performed by using Sigma Plot (San Jose, CA) with log-rank
significance tests. A P value of less than 0.05 was considered significant.
RESULTS
CCL3 Promotes Radiation-Induced Injury
To determine whether levels of CCL3 are increased by radia-
tion of lung tissues, we irradiated two lung-derived cell lines,
MRC5 normal lung fibroblasts and SKLu-1 lung adenocarci-
noma cells, with a single dose of 5 Gy and supernatants ware
collected 12 hours later for CCL3 protein quantitation. Al-
though not detectable (,1.5 pg/ml) before irradiation, CCL3
production increased significantly in both the MRC5 (5.22 6
1.23 pg/ml) and SKLu-1 (8.12 6 2.49 pg/ml) cell lines after
irradiation. Thus, CCL3 is increased by radiation in both normal
and malignant lung-derived cell lines.
We next investigated if pulmonary levels of CCL3 are also
induced in vivo by thoracic irradiation. C57Bl/6J mice were
irradiated and harvested at various time points thereafter for
analysis of lung CCL3 protein. By 1 week after irradiation, CCL3
levels dropped to below levels seen in untreated mice (possibly
due to the death of chemokine-producing cells). By 2 weeks after
irradiation, CCL3 had returned to baseline levels, and continued
to rise further, reaching a peak at 4 weeks, and a second peak at
20 weeks after irradiation (Figure 1A). The mRNA expression of
CCL3 showed a similar pattern in lungs of irradiated mice with
peak expression at 4 and 20 weeks after irradiation (Figure 1B).
To investigate the relevance of CCL3 expression to radiation-
induced lung injury, we compared radiation-induced responses in
WT and CCL3-deficient mice. As expected, about half of the
WT mice died by 32 weeks after irradiation (Figure 2A).
However, only 16% of the Ccl32/2 mice died after thoracic
Figure 1. Thoracic irradiation–induced CC chemokine ligand (CCL) 3
production in vivo. Wild-type mice were irradiated and whole lungs
harvested at the indicated times for (A) CCL3 protein content by ELISA
or (B) mRNA expression. Values represent ratios of increase compared
with unirradiated control mice (0 wk). Values shown are the means
(6SEM). *P , 0.05 compared with the unirradiated controls (n 5 3–6
mice per time point).
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irradiation. Therefore, CCL3 contributes to thoracic radiation-
induced mortality. To determine if the difference in mortality
between WT and CCL3-deficient mice was related to differ-
ences in fibrosis, mice were killed at 32 weeks after irradiation,
and their lungs were examined for levels of collagen using
a hydroxyproline assay. As expected, there was more collagen
in lungs of irradiated WT mice than in their untreated coun-
terparts (Figure 2B). Although lung collagen also increased in
Ccl32/2 mice, this increase was significantly less than in WT
mice (11 versus 27%). At 32 weeks after irradiation, a number
of lung histologic changes were noted in WT mice, including
inflammation, increased septal cellularity and thickness, in-
creased collagen deposition, with disturbed architecture and
organizing alveolitis (Figures 2C and 2D). In contrast, Ccl32/2
mice had less inflammation, no significant septal thickening,
only rare and small foci of collagen deposition, and relatively
intact lung architecture.
CCR1, but Not CCR5, Promotes Radiation-Induced
Injury and Mortality
CCL3 binds and signals through the chemokine receptors,
CCR1 and CCR5 (6). To investigate whether either of these
two receptors mediates radiation-induced injury, we prepared
RNA from lungs of mice at various times after irradiation.
Analysis of this RNA by quantitative RT-PCR revealed that
CCR1 expression was significantly increased by 4 weeks after
irradiation, reached a fivefold increase over the baseline levels
by 20 weeks, and remained elevated through 32 weeks (Figure
3). By contrast, CCR5 expression in the lung did not increase
until displaying a slight (1.53) increase at 12 weeks after
irradiation, after which it remained elevated until Week 32.
Notably, the increased CCR1 expression at 4 and 20 weeks
closely paralleled the increases seen with CCL3 expression,
suggesting that CCL3 may directly lead to recruitment of
CCR1-expressing cells.
Figure 2. Survival and fibrosis in irradiated wild-type (WT) and Ccl32/2 mice. (A) Survival after thoracic radiation. WT (n 5 63) and Ccl32/2 mouse
(n 5 31) survival at the indicated number of weeks after irradiation. *P , 0.001, compared with irradiated WT mice. (B) Hydroxyproline content in
the lung. Right lungs from WT and Ccl32/2 mice were harvested 32 weeks after radiation, and hydroxyproline assays were conducted. Ccl32/2 CN,
unirradiated Ccl32/2 (n 5 9); Ccl32/2 IR, irradiated Ccl32/2 (n 5 7); WTCN, unirradiated WT (n 5 9); WTIR, irradiated WT (n 5 9). (C ) Whole
sections of Masson’s trichrome (MT)–stained lungs of irradiated WT and Ccl32/2 mice. (D) MT-stained sections viewed at 203 magnification.
Figure 3. CC chemokine receptor (CCR) 1 and CCR5 mRNA levels
after thoracic irradiation. Lung total RNA was prepared from unirradi-
ated WT mice and from irradiated WT mice at the indicated times after
irradiation. Ccr1 and Ccr5 mRNA levels were assessed by quantitative
PCR, and normalized to levels of glucuronidase b RNA. Values shown
represent relative levels of Ccr1 and Ccr5 mRNA compared with levels
in unirradiated mice (n 5 5–9 mice per group). Values shown are the
means (6SD). *P , 0.05, irradiated mice compared with unirradiated
controls (0 wk).
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To determine more directly the requirement of CCR1 and
CCR5 in radiation-induced injury, we studied mice separately
lacking these two chemokine receptors. Compared with irradi-
ated WT mice, Ccr12/2 mice had significantly improved sur-
vival. By contrast, there was no difference in radiation-induced
mortality between WT and Ccr52/2 mice (Figure 4A). As seen
previously, radiation increased the hydroxyproline content of
WT mice (z27%). Surprisingly, this increase was even greater
in Ccr52/2 mice (z50%). In contrast, but similar to what we
saw in CCL32/2 mice, hydroxyproline increases were minimal
(z4%) in irradiated Ccr12/2 mice (Figure 4B). Staining of lung
sections revealed that both inflammation and collagen accumu-
lation were also greater in Ccr52/2 mice than in their WT
counterparts (Figures 4C and 4D). In contrast, Ccr12/2 mice
had negligible inflammation and fibrosis. Quantitative digital
imaging analyses showed that, when compared with untreated
controls, both the irradiated WT and Ccr52/2 mice, but not
Ccr12/2 mice, had increased septal thickening, consistent with the
hydroxyproline data (Figure 4E). Together, these findings
suggest that the binding of CCL3 to CCR1 promotes radiation-
induced injury, inflammation, and mortality. By contrast, binding
of CCL3, or of another chemokine, to CCR5 appears to protect
against radiation injury, because Ccr52/2 mice displayed more
injury than WT mice.
Decreases in lung compliance accompany and contribute to
thoracic radiation-induced mortality. Accordingly, we assessed
the impact of radiation on lung compliance in Ccr12/2 mice and
Ccr52/2 mice. As expected, WT mice displayed decreased
Figure 4. Survival and fibrosis in irradiated WT, Ccr12/2, and Ccl52/2 mice. (A) Survival of mice at the indicated times after irradiation. (B)
Hydroxyproline content of right lungs of nonirradiated mice and irradiated mice at 32 weeks after irradiation. CCR12/2CN, unirradiated CCR12/2
mice (n 5 14); CCR12/2IR, irradiated CCR12/2 mice (n 5 13); CCR52/2CN, unirradiated CCR52/2 mice (n 5 12); CCR52/2IR, irradiated CCR52/2
mice (n 5 7); IR, irradiated; nonIR, nonirradiated control mice; WTCN, unirradiated WT mice (n 5 9); WTIR, irradiated WT mice, n 5 9. (C ) Whole
sections of MT-stained lungs of irradiated WT, Ccr12/2 mice, and Ccr52/2 mice. (D) MT-stained sections viewed at 203 magnification. (E )
Quantitative measurements of lung tissue abnormalities by morphometric analysis of lung sections. Ten 53 images of each lung section were
analyzed to quantify septal thickening as a measure of lung inflammation and fibrosis. Values shown are means (6SD) of 4–8 lung sections per
group. *P , 0.05, compared with unirradiated WT controls.
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compliance and increased elastance after irradiation (see Figure
E1 in the online supplement). Similar changes were seen in and
Ccr52/2 mice, but not in Ccr12/2 mice. Taken together, these
data suggest that CCL3, acting through CCR1, promotes radi-
ation injury, lung inflammation, and fibrosis, with consequent
impaired lung compliance and, ultimately, death.
In view of our finding that Ccr12/2 mice, but not Ccr52/2
mice, were protected from radiation-induced injury, we focused
our subsequent studies on potential mechanisms linking CCL3
and CCR1 to fibrosis. It was unclear from our studies, thus far, if
these molecules were required primarily during this late phase,
or during the early inflammatory phase. To test this, we studied
the progression of pulmonary inflammation over the 32 weeks
between radiation and fibrosis. In lungs of irradiated WT mice,
there was an initial decrease in total CD451 leukocytes (Figure
5A), including CD41 and CD81 lymphocytes, during the first
week after irradiation (Figures 5B and 5C). However, levels of
each of these cell types gradually increased, and reached high
levels throughout the inflammatory phase between 12 and 20
weeks after irradiation. The initial decrease in leukocytes seen
in WT mice was also seen in Ccr12/2 mice. However, during the
inflammatory phase, Ccr12/2 mice had fewer CD451 leuko-
cytes, including CD41 and CD81 lymphocytes. Interestingly,
macrophages, which are thought to be important during the
development of fibrosis (23, 24), were significantly decreased in
Ccr12/2 mice after irradiation, but were increased in WT mice,
and this difference was evident through nearly the entire 32
weeks after irradiation (Figure 5D). CCL3-deficient mice also
showed decreases in CD41 and CD81 T cells, and macrophages
compared with WT mice after thoracic radiation (S. L. Kirby,
unpublished data). The decreased inflammation in Ccr12/2 mice
compared with WT mice was also evident by microscopic
examination of lung tissue (Figure 5E). Of note, there were no
differences in WT compared with CCR1-deficient mice in
neutrophils (Gr11 cells), T regulatory cells (FoxP31 CD41), or
B cells (CD191 CD201). Taken together, these findings suggest
that binding of CCL3 to CCR1 during the first few weeks after
irradiation contributes to radiation-induced lung inflammation.
Several reports have shown that cytokines produced by T
helper (Th) 2 lymphocytes are associated with fibrosis (25, 26).
Figure 5. Leukocyte infiltration in the lung. Lungs were harvested at the indicated times after irradiation, and leukocytes prepared from them. (A–D)
Antibody staining of cells for the indicated surface molecules; CD45, CD4, CD8, and F4/80. Values shown are the means (6SEM) of three to six mice
per group. *P , 0.05, compared with unirradiated controls of the same genotype. #P , 0.05, compared with irradiated WT mice at the same time
point. (E ) hematoxylin and eosin–stained sections of lung tissue. Arrows indicate foamy macrophages.
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Accordingly, we studied levels of the Th2 cytokines, IL-4 and
IL-13, and compared them to levels of the Th1 cytokine, IFN-g
(Figures 6A–6C). Both IL-4 and IL-13 were increased in lungs
of irradiated WT mice, with increases in IL-4 preceding those of
IL-13 (Figures 6A and 6B). However, no significant increases in
these cytokines were seen in Ccr12/2 mice. Instead, the latter
animals had increased levels of the Th1 cytokine, IFN-g (Figure
6C). This finding demonstrates that CCR1 is required for the
development of a Th2 environment in the lung after thoracic
radiation, and suggests that CCR1-mediated recruitment of Th2
cells might contribute to radiation-induced fibrosis.
Because pulmonary fibrosis is associated with TGF-b1 pro-
duction (27), we compared levels of this cytokine in WT, Ccl32/2,
and Ccr12/2 animals at 32 weeks after irradiation. TGF-b1
levels were significantly increased in irradiated WT mice, but
not in irradiated Ccl32/2 or Ccr12/2 mice (Figure E2).
The CCR1 Inhibitor, BX-471, Attenuates Radiation-Induced
Lung Injury
The protection from the lung inflammation and fibrosis seen in
Ccl32/2 mice and Ccr12/2 mice suggested that pharmacologic
inhibition of CCL3 binding to CCR1 might diminish or prevent
radiation-induced lung injury. One of the most extensively
studied small molecule inhibitors of CCR1 is BX-471, which
can ameliorate inflammation in several rodent disease models
(21, 22, 28, 29). Accordingly, we tested the ability of BX-471 to
protect WT mice from radiation-induced injury and death. We
began administration of this inhibitor at 3 weeks after irradia-
tion (14.5 Gy), because it was shortly after this time that both
leukocytes and CCR1 expression begin to increase in our model
(Figure 3). The inhibitor, BX-471, was given twice daily for 4
weeks. Control irradiated mice received vehicle (40% cyclodex-
trin) only for 4 weeks. This short course of BX-471 conferred
nearly complete protection from radiation-induced lung fibrosis,
as shown by hydroxyproline assays and by histologic analyses of
lung tissue (Figures 7A and 7B). The survival at 32 weeks was
significantly improved by treatment with the inhibitor (96%
[BX-471 treated] versus 67% [vehicle treated]). The inhibitor
also prevented the decline in lung function seen in irradiated
mice that received vehicle only (Figure E3). Similar cohorts of
irradiated WT mice treated for 8 weeks with BX-471 (Week 3 to
Week 11 after irradiation) showed similar, but not better,
results. Thus, short-term treatment with BX-471 was sufficient
to prevent radiation-induced fibrosis.
The ability of BX-471 to prevent radiation-induced fibrosis
and decline in lung function in our model suggests that this
compound might also prevent these complications in humans.
Patients receive thoracic radiation for tumors. A number of
tumors express CCR1 (30, 31), and CCR1 has been implicated,
either directly or through host defense, as a promoter of tumor
growth or metastases (32–35). Thus, it is important to examine
whether BX-471 may alter tumor growth. To investigate this, we
injected Lewis lung carcinoma cells into C57BL/6 mice that also
received BX-471 (or vehicle only in control mice). The trans-
planted tumor cells grew to an equivalent extent in untreated
WT mice as in BX-471–treated WT mice or vehicle-treated
Ccr12/2 mice (Figure E4). Therefore, we are encouraged that
BX-471 does not accelerate growth of these tumor cell lines.
DISCUSSION
The development of pulmonary fibrosis is associated with prior
inflammation, but a direct and causal relationship between
these two events has not been established. In the model used
here, genetic deletion of CCL3 or its receptor, CCR1, protected
against both inflammation and fibrosis, suggesting that these two
events were causally linked. However, with regard to fibrosis,
these experiments did not identify a temporal requirement of
CCL3 and CCR1 during only the inflammatory phase, during
only the fibroproliferative phase, or during both phases of the
Figure 6. T helper (Th) 1 and Th2 cytokine gene expression after
radiation. Lung total RNA was prepared from unirradiated WT mice and
from irradiated WT mice at the indicated times after irradiation. mRNA
levels were assessed by quantitative PCR and normalized to levels of
glucuronidase b RNA. Values shown represent relative levels compared
with levels in unirradiated mice. (A) IL-4; (B) IL-13; (C ) IFN-g. Values
shown are the means (6SD) of six to nine mice per group. *P , 0.05,
compared with unirradiated controls of the same genotype.
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disease. Inhibitors are particularly valuable in this regard,
because they can be selectively administered during one phase,
but not the other. Our finding, that inhibitor-mediated blockade
of CCR1 during a 4-week period during the onset of the inflam-
matory phase is sufficient to prevent both the lung inflammation
and fibrosis in WT mice, provides strong evidence that the
inflammatory phase is required for development of the sub-
sequent fibroproliferative phase.
We found that the deficiencies of CCL3 receptors, CCR1
and CCR5, had different impacts on radiation lung injury.
Whereas Ccr12/2 mice had relatively little disease compared
with WT mice, Ccr52/2 mice had more severe disease than WT
mice. The selective requirement of CCR1 for fibrosis in this
model is consistent with the previous findings that anti-CCL3
antibodies, as well as anti-CCR1 antibodies, reduce bleomycin-
induced inflammation and collagen deposition (36–38), that
Ccr12/2 mice are protected from hepatic fibrosis (39) and renal
fibrosis (29), and that BX-471 protects mice against acute
pancreatitis-associated lung injury by modulating neutrophil
recruitment (40). However, the exacerbated disease seen in
Ccr52/2 mice was not anticipated. The dramatic difference in
disease severity between these two strains might derive from the
different leukocyte subsets that are recruited by these two
chemokine receptors. Whereas CCR1 is reported to promote
Th2 cell recruitment (41), CCR5 is expressed on Th1 cells and
promotes Th1-type immune responses (42). The ability of Th2
cytokines to activate fibroblasts and promote extracellular
matrix deposition and remodeling (43) suggests that CCR1
can enhance fibrosis by recruiting Th2 cells to the lung. By
contrast, the Th1 cytokine, IFN-g, has antifibrotic effects, pos-
sibly by inhibiting the function of myofibroblasts (44, 45). Thus,
CCR5 might inhibit the development of fibrosis by recruiting
Th1 cells to the lung. This explanation is supported by our
finding that Th2 cytokines began to increase at about 4 weeks
after radiation in WT mice, but not in Ccr12/2 mice. An
alternative explanation is that CCR5 promotes the recruitment
T regulatory cells, as it is proposed to do in other settings (46).
The severity of disease in Ccl32/2 mice was intermediate
between that of Ccr12/2 mice and of Ccr52/2 or WT mice,
suggesting that, whereas CCL3 recruits effector cells through
CCR1, it also recruits protective cells through CCR5. Disease in
Ccl52/2 mice was also intermediate between WT and Ccr12/2
mice (S.L.K., unpublished data). Additional studies will be
required to characterize more extensively the phenotype and
function of each of these cell types, and the impact of CCR1 and
CCR5 on their recruitment.
Figure 7. Pulmonary fibrosis in irradiated WT
mice treated with BX471. (A) Collagen levels in
the right lung as determined by measurements
of hydroxyproline at 32 weeks after irradiation.
CNTL, unirradiated and untreated, number of
mice per group (n 5 12); IR1BX471, irradiated
and treated with daily subcutaneous injection
of BX-471 at 30 mg/Kg of body weight from
Week 3 to Week 7 after irradiation (n 5 19).
IR1vehicle, irradiated and treated with daily
subcutaneous injection of vehicle (40% cyclo-
dextrin) from Week 3 to Week 7 after irradia-
tion (n 5 16). (B) Whole sections of MT-stained
lungs of irradiated mice treated with BX471 or
vehicle. (C ) Representative MT-stained lung
sections of mice treated with BX471 or vehicle.
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The data presented here suggest that radiation-induced
fibrosis is mediated by the binding of CCL3 to its receptor,
CCR1, whereas binding of this chemokine to a different receptor,
CCR5, protects against fibrosis. Importantly, selective blockade
of CCR1 with the antagonist, BX-471, effectively protects WT
mice from the lung injury and fibrosis that is otherwise seen in
these animals after radiation. These novel findings suggest that
blockade of the CCL3/CCR1 signaling pathway might also
protect human patients from thoracic radiation–induced pulmo-
nary fibrosis.
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